Hepatitis C virus (HCV) is the prototype member of the Hepacivirus genus within the family Flaviviridae. The virus is transmitted almost exclusively by the parenteral route, and acute infections, which are frequently subclinical, progress to chronicity in about 70% of cases. Persistent HCV carriers may develop liver cirrhosis, hepatocellular carcinoma, and end-stage liver disease. Despite an efficient preventive campaign based on the identification of HCV-infected blood donors, the prevalence of the virus among American young adults has not declined (35). Recent advances have improved treatment options for infections with certain viral genotypes, although limitations in efficacy remain and a preventive vaccine is not available.HCV is an enveloped virus, with a positive-sense, singlestranded RNA genome. The genome is translated into a polyprotein which is proteolytically processed into 10 individual proteins (reviewed in reference 64). The structural proteins, core protein (C) and two envelope glycoproteins (E1 and E2), form the physical viral particle; C functions to encapsidate the RNA genome, while E1 and E2 mediate virus attachment and entry into host cells. E1 and E2 are highly glycosylated type I transmembrane proteins with an N-terminal ectodomain. Residues within the transmembrane domains are important for heterodimerization and dimer retention in the endoplasmic reticulum (ER) (22,46). Replacement of the E1 or E2 transmembrane domains can direct transport of the corresponding chimeric proteins to the plasma membrane (1, 10). E2 also encompasses well-conserved antibody neutralization determinants, which are located near the binding sites for viral entry factors CD81 and scavenger receptor B1 (20,29). There is also some evidence for the existence of neutralizing determinants in E1 (45). Patient neutralizing antibodies have been identified that target virus interactions with its coreceptors and block glycoprotein-mediated membrane fusion (31).A major hurdle in the development of an effective HCV vaccine is the lack of an immunization strategy to elicit broadly protective antibodies and sustained cell-mediated immunity (32, 66). Studies with chimpanzees have shown the importance of total anti-E1/E2 antibody titers in conferring protection (15). Moreover, neutralizing immunity and functional CD4 ϩ and CD8 ϩ Tcell responses induced early in HCV infection correlate with clearance or viral control in patients (7,37,51).In contrast, the measles virus (MV) vaccine has an outstanding record of efficacy and safety. The MV Moraten vaccine strain is credited with the temporary elimination of indigenous measles transmission on the American continent (14), and the World Health Organization is implementing a global measles eradication program (72,73). After completion of the two-dose vaccination schedule, nearly 100% of recipients develop lasting neutralizing immunity that may be lifelong (2). In addition, the availability of established production methods makes MV an appealing platform for delivering foreign antigens (r...